We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Human Antibody Kills Cancer Cells in Mice

By Biotechdaily staff writers
Posted on 19 Dec 2003
A human antibody binds to a unique site on CD20 target cells and appears to stop growth of B-cell tumors in immuno-compromised mice far more effectively than either placebo or a marketed treatment called rituximab.

Called HuMax-CD20, the antibody was evaluated in a mouse model in which disseminated outgrowth of human B-cell tumor cells is followed by optical imaging. More...
Tumors were induced by inoculating Daudi cells, a CD20-expressing human lymphoma cell line, which readily grows in immuno-deficient (SCID) mice. For this model, Daudi cells were transfected with luciferase, which makes them bioluminescent. The fact that HuMax-CD20 binds to a unique site on CD20 target cells may help to explain why the antibody has outperformed other CD20 antibodies in a variety of preclinical studies.

"We have observed the unusually good performance of HuMax-CD20 in a large number of preclinical tests, and have been conducting research to help explain why the antibody binds to and kills the disease target so effectively,” said Lisa N. Drakeman, Ph.D., CEO of Genmab (Copenhagen, Denmark; www.genmab.com), which is developing the new therapeutic.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Thyroid Test
Anti-Thyroid EIA Test
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.